JAMA reports fluvoxamine as potential early treatment for COVID-19
The COVID-19 Early Treatment Fund (CETF) announced that <i>JAMA</i>, <i>The Journal of the American Medical Association</i>, published the results of a Washington University School of Medicine in St. Louis double-blind, randomized controlled clinical trial that investigated whether the...
www.eurekalert.org
only a few hundred cases where treated but none had to be hospitalized or died. this seem to reduce the severity of covid to that of a regular flu.